Last reviewed · How we verify

NCT05270629

Supermicrosurgical Lymphvenous Bypass Intervention for Treatment

Status unknown Last updated 8 March 2022
What this trial tests

trial testing Antegrade and retrograde anastomoses in Lymphedema of Leg in 87 participants. Status unknown.

Timeline
6 September 2021
Primary endpoint
31 August 2022
5 September 2022

Quick facts

Lead sponsorChang Gung Memorial Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment87
Start date6 September 2021
Primary completion31 August 2022
Estimated completion5 September 2022
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Chang Gung Memorial Hospital

Who can join

Adults 18 to 100, any sex, with Lymphedema of Leg. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: In addition to antegrade anastomosis, retrograde anastomosis has been thought to offer further improvements after lymphaticovenous anastomosis (LVA) by bypassing the retrograde lymphatic flow. However, this concept has yet to be validated. The aim of this study was to determine the impacts on outcomes of performing both retrograde and antegrade anastomosis, as compared to antegrade-only anastomosis for treating lower limb lymphedema.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lymphedema of Leg

Currently open trials in the same condition.

Other Chang Gung Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05270629.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing